AbbVie has agreed to buy Apogee for $10.9 billion, securing an inflammatory disease drug in the drugmaker's largest acquisition in more than half a decade. The transaction arrives as merger and acquisition activity across the pharmaceutical sector has accelerated broadly.
What AbbVie Is Buying
The $10.9 billion price transfers Apogee's inflammatory disease asset to AbbVie. The announcement did not identify the drug by name, disclose its development stage, or detail payment structure. At that headline figure, the deal represents a level of external spending AbbVie has not matched in over five years, signaling a decision to acquire pipeline rather than build it.
A Sector in Deal Mode
The AbbVie-Apogee agreement fits a pattern that has defined pharmaceutical M&A in the current cycle: established drugmakers deploying balance-sheet capacity to buy assets held by smaller, more specialized companies. The source of the deal — an inflammatory disease drug developed outside AbbVie — reflects a broader industry dynamic in which large companies increasingly look externally to replenish or extend their therapeutic portfolios. The surge in sector M&A described in the announcement suggests AbbVie is not alone in that approach.
Source is limited to deal value, buyer, seller, therapeutic focus, and relative deal size. No drug name, development stage, premium, or additional financial terms were available for inclusion.